Identical Elements Are Not Required for the Presumption of Obviousness Based on Overlapping Ranges
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
ALMIRALL, LLC v. AMNEAL PHARMACEUTICALS LLC
Before Lourie, Chen, and Cunningham. Appeal from the Patent Trial and Appeal Board.
Summary: Presumption of obviousness based on overlapping ranges applied where a prior-art reference disclosed an element in the claimed range that was similar but not identical to the claimed element.
Amneal petitioned for inter partes review of Almirall’s patent. The challenged claims recite methods of skin treatment using topical formulations of compounds in certain concentrations. These compounds include a copolymer called A/SA, which acts as a thickening agent. Amneal argued that the challenged claims were obvious over a patent publication called Garrett in view of either two secondary references. With one exception, Garrett discloses each claimed compound in concentrations that encompass, overlap with, or abut the concentrations claimed. The exception is that Garrett does not teach using A/SA as its thickening agent; instead, the preferred thickening agent in Garrett is a polymer in a class called carbomer. Each secondary reference discloses using A/SA as a thickening agent in concentrations that overlap with the claimed concentrations. The Board applied a presumption of obviousness based on overlapping ranges and found that Almirall did not overcome that presumption. It therefore held the challenged claims unpatentable. Almirall appealed.
On appeal, Almirall argued that the Board erred in presuming obviousness based on overlapping ranges. Specifically, it argued that Garrett does not disclose ranges for A/SA thickeners and therefore no single reference discloses all of the claimed ranges. The Court disagreed. It cited the Board’s factual findings of similarity between Garrett’s carbomer thickeners and the claimed A/SA thickeners, noting expert testimony that supported those findings. Separately, the Court noted that the case does not depend on overlapping ranges but is simply a case of substituting one known thickening agent for another. It held there was substantial evidence that a person of ordinary skill in the art would have been motivated to combine Garrett with either of the secondary references to arrive at the claims with a reasonable expectation of success. Accordingly, the Federal Circuit affirmed the Board’s obviousness determination.
Editor: Paul Stewart
Written by: Joshua C. Loader & Justin J. Gillett
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…